Table 3.
Comparison of Proliferation (Ki67) and Angiogenesis (CD31) Between CTCLs and Lymphoma Mimickers (Non-Neoplastic Dermatoses)
| Expression | Non-Neoplastic n=22 | Lymphoma n=59 | MF n=49 | Non-MF CTCL n=10 | Early Stage MF n=39 | Late Stage MF n=10 | Classic MF n=33 | MF Variants n=16 |
|---|---|---|---|---|---|---|---|---|
| Ki67 | ||||||||
| Median | 2 | 8 | 7 | 55 | 5 | 35 | 8 | 4 |
| Range | 1–25 | 1–75 | 1–70 | 40–75 | 1–30 | 20–70 | 2–70 | 1–55 |
| Low index (n, %) | 21(95.5%) | 37(62.7%) | 37(75.5%) | 0 (0.0) | 36(92.3%) | 0 (0.0) | 22(66.7%) | 14(87.5%) |
| High index (n, %) | 1(4.5%) | 22(37.3%) | 12(24.5%) | 10(100.0%) | 3(7.7%) | 10(100.0) | 11(33.3%) | 2(12.5%) |
| Test of significance with non-neoplastic |
χ2=8.45 p=0.004* |
χ2=4.04 p=0.04* |
FET p<0.001* |
FET p=1.0 |
FET p<0.001* |
χ2=6.41 p=0.01* |
χ2=4.27 p=0.03* |
|
| Test of significance between subgroups | Vs. total MF χ2=20.25 p<0.001* Vs. late MF FET P=1.0 |
FET p<0.001* |
χ2=4.27 p=0.03* |
|||||
| CD31 | ||||||||
| Median | 20 | 37 | 27 | 71 | 25 | 68 | 38 | 21.5 |
| Range | 9–59 | 12–94 | 12–79 | 61–94 | 12–60 | 58–79 | 20–79 | 12–62 |
| Test of significance with non-neoplastic | Z=4.31 p<0.001* |
Z=2.96 p=0.003* |
Z=4.47 p<0.001* |
Z=2.08 p=0.03* |
Z=4.22 p<0.001* |
Z=3.93 p<0.001* |
Z=3.71 p<0.001* |
|
| Test of significance between subgroups | Vs. total MF z=4.28 p<0.001* Vs. late MF z=0.94 p=0.35 |
Z=4.61 p<0.001* |
Z=3.71 p<0.001* |
|||||
| Test of significance between CD31 and Ki67 | rs=0.922 <0.001* |
|||||||
Notes: χ2; chi-Square test, Z; Mann–Whitney U-test; rs; Spearman correlation coefficient, *p value is statistically significant if ≤0.05.
Abbreviation: FET, Fischer exact test.